Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, INmune Bio's Enterprise Value is $26.68 Mil.
INmune Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-19.16 Mil. Therefore, INmune Bio's EV-to-OCF for today is -1.39.
The historical rank and industry rank for INmune Bio's EV-to-OCF or its related term are showing as below:
INMB'
s EV-to-OCF Range Over the Past 10 Years
Min: -34.93 Med: -4.68 Max: -0.27
Current: -1.39
During the past 10 years, the highest EV-to-OCF of INmune Bio was -0.27. The lowest was -34.93. And the median was -4.68.
INMB's EV-to-OCF is ranked worse than 60.85% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs INMB: -1.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
INmune Bio's share price for today is $1.75.
INmune Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
INmune Bio EV-to-OCF Related Terms
INmune Bio EV-to-OCF Historical Data
* Premium members only.
The historical data trend for INmune Bio's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, INmune Bio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where INmune Bio's EV-to-OCF falls into.
INmune Bio's current Enterprise Value is $26.68 Mil.
INmune Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio (INMB) has a EV-to-OCF of -1.39 as of Aug. 01, 2026. According to the industry distribution chart, INmune Bio ranks #858 out of 1410 companies in the Biotechnology industry, placing it in the top 60.9%.
Is INmune Bio's EV-to-OCF too high?
INmune Bio's current EV-to-OCF is -1.39. Based on the distribution chart, INmune Bio ranks #858 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, INmune Bio has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's EV-to-OCF compare to FLNA and DYAI?
According to the Biotechnology industry distribution chart, INmune Bio ranks #858 out of 1410 companies for EV-to-OCF. This places INmune Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. INmune Bio's current EV-to-OCF is -1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.79, compared to a current price of $1.75 — trading 2.2% below its estimated fair value. The current EV-to-OCF is -1.39. INmune Bio's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For INmune Bio (INMB), the current EV-to-OCF is -1.39 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.75 is trading 2.2% below its estimated GF Value™ of $1.79.
GuruFocus considers INmune Bio to be Fairly Valued.
Key valuation signals for INMB:
EV-to-OCF: -1.39
GF Value™: $1.79 vs. price of $1.75 (2.2% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
57GF Score
Get the complete analysis for INMB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
